• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich,
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …

2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …

Antiplatelet therapy is key to reducing local thrombotic complications and systemic
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …

Члены Комитета экспертов подтвердили отсутствие финансовой поддержки/конфликта
интересов. В случае сообщения о наличии конфликта интересов, член (ы) Комитета …

always refer to the full text version, which is freely available on the ESC and EACTS
websites. The National Societies of the ESC are encouraged to endorse, translate, and …

Background Whether guided selection of antiplatelet therapy in patients undergoing
percutaneous coronary intervention (PCI) is effective in improving outcomes compared with …

Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the standard
treatment for patients undergoing percutaneous coronary intervention. The availability of …

These Guidelines represent the third time that the ESC and EACTS have brought together
cardiologists and cardiac surgeons in a joint Task Force to review the ever-increasing body …

Background In patients with acute myocardial infarction receiving potent antiplatelet therapy,
the bleeding risk remains high during the maintenance phase. We sought data on a uniform …